Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.43 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8623878 | 0.87 | PTGER1 (0.62) | PTGER1P4HTMTRPV3ALKBH1ALDH1A1 | |
| SCHEMBL15898833 | 0.84 | PTGER1 (0.53) | KCNH2PTGER1P4HTMGRM5TRPV3 | |
| SCHEMBL289601 | 0.83 | TDP1 (0.51) | PTGER1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL8837769 | 0.83 | F10 (0.46) | PTGER1TRPV3 | |
| SCHEMBL16108509 | 0.82 | LMNA (0.50) | PTGER1TRPV3ALDH1A1 | |
| SCHEMBL2524154 | 0.81 | L3MBTL1 (0.52) | GRM5TRPV3 | |
| SCHEMBL23121605 | 0.79 | TRPV3 (0.50) | PTGER1PARP10GRM5TRPV3ALKBH1 | |
| SCHEMBL3924036 | 0.79 | MAPK8 (0.54) | KCNH2OPRM1PARP10 | |
| SCHEMBL9353812 | 0.79 | TRPV3 (0.50) | PTGER1TRPV3ALDH1A1 | |
| SCHEMBL25465653 | 0.79 | PTGER1 (0.46) | PTGER1P4HTMGRM5TRPV3ALKBH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148242-B2 | N-formyl hydroxylamine compounds, compositions and methods of use | NOVARTIS AG (CH) | 2006-12-12 | — | — | US | disclosed |
| EP-1401828-B1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARM INC (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1401828-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | Vicuron Pharmaceuticals, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | VICURON HOLDINGS LLC | 2003-03-06 | — | — | US | disclosed |
| WO-2002102790-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARMACEUTICALS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | PDF, HNMT, AADAC | KCNH2 4802/4885OPRM1 1050/4885PTGER1 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.